TY - JOUR T1 - Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer. AU - Kobayashi,Takashi, AU - Nishizawa,Koji, AU - Mitsumori,Kenji, PY - 2006/7/1/pubmed PY - 2006/12/9/medline PY - 2006/7/1/entrez SP - 198 EP - 203 JF - Scandinavian journal of urology and nephrology JO - Scand J Urol Nephrol VL - 40 IS - 3 N2 - OBJECTIVE: To evaluate the process of hormonal recovery after cessation of luteinizing hormone-releasing hormone (LHRH) agonist treatment in patients who had received long-term LHRH agonist therapy for prostate cancer. MATERIAL AND METHODS: Men who had successfully undergone androgen deprivation therapy with only monthly LHRH agonist therapy for > 30 months were enrolled and the administration of LHRH agonist was discontinued. Serum total testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prostate-specific antigen (PSA) were measured before the cessation of LHRH agonist therapy and every 4 weeks thereafter, and the administration of LHRH agonist remained suspended until the total testosterone level recovered to > 50 ng/dl. RESULTS: Ten patients were enrolled in the study. The median (range) castration period and the levels of serum LH, FSH, total testosterone and PSA at cessation of therapy were 39 (30-56) months,<0.5 (<0.5-1.8) mIU/ml, 6.4 (3.0-15.9) mIU/ml, 15.3 (5.8-34.7) ng/dl and 0.13 (0.02-0.89) ng/ml, respectively. Testosterone recovered to > 50 ng/dl in all cases. There were large variations in the times required for recovery of LH and FSH (30-100 days) and serum testosterone (30-330 days). PSA began to increase at various testosterone levels, and there was a large variation (0-83%; median 41%) in the ratio of the androgen suppression (testosterone < 50 ng/dl) time to the period of LHRH agonist cessation. CONCLUSIONS: There was considerable variation in the hypothalamus-pituitary-testicular hormone profiles during recovery from long-term medical castration. These findings are noteworthy when interruption of androgen deprivation therapy is applied with the intention of delaying the progression of hormone-refractory cancer or improving the patient's quality of life. SN - 0036-5599 UR - https://www.unboundmedicine.com/medline/citation/16809259/Individual_variation_of_hormonal_recovery_after_cessation_of_luteinizing_hormone_releasing_hormone_agonist_therapy_in_men_receiving_long_term_medical_castration_therapy_for_prostate_cancer_ L2 - https://www.tandfonline.com/doi/full/10.1080/00365590600641533 DB - PRIME DP - Unbound Medicine ER -